✦ LIBER ✦

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

✍ Scribed by Teemu T. Junttila; Guangmin Li; Kathryn Parsons; Gail Lewis Phillips; Mark X. Sliwkowski

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

515 POSTER Trastuzumab-mertansine (T-DM1

✍ T. Junttila; C. Fields; G. Li; L. Crocker; K. Parsons; L. Berry; K. Totpal; G. L 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Preclinical safety profile of trastuzuma

✍ Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph; Tibbitts, Jay; Kaur, Sur 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 935 KB

A phase 1 study of weekly dosing of tras

✍ Muralidhar Beeram; Ian E. Krop; Howard A. Burris; Sandhya R. Girish; Wei Yu; Mic 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB

Ado-trastuzumab emtansine (T-DM1): a nov

✍ Baron, J. M.; Boster, B. L.; Barnett, C. M. 📂 Article 📅 2014 🏛 SAGE Publications 🌐 English ⚖ 165 KB

Indirect Comparison Analysis to Evaluate

✍ Benito Garcia, E.; Hersberger, V.; Takyar, S.; Moser, A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

A population pharmacokinetic/pharmacodyn

✍ Bender, Brendan C.; Schaedeli-Stark, Franziska; Koch, Reinhold; Joshi, Amita; Ch 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 755 KB